叶酸、腺苷钴胺联合胃复春治疗幽门螺杆菌阴性慢性萎缩性胃炎的临床效果观察  

Clinical Observation of Folic Acid, Cobamamide and Weifunchun in the Treatment of Helicobacter Pylori-negative Chronic Atrophic Gastritis

作　　者：薛建波 仝建军 徐涛[1] 马丽 曹智强[1] 

机构地区：[1]首都医科大学大兴医院,北京120600

出　　处：《中国医药指南》2018年第7期11-12,共2页Guide of China Medicine

摘　　要：目的探讨叶酸、腺苷钴胺联合胃复春治疗幽门螺杆菌阴性慢性萎缩性胃炎的临床疗效。方法选取2015年5月至2016年8月我院收治的幽门螺杆菌阴性慢性萎缩性胃炎患者74例,将其随机分为对照组和实验组两组,每组37例。对照组采用胃复春进行治疗,实验组采用胃复春联合叶酸、腺苷钴胺进行治疗,治疗12周结束后对2组临床疗效、胃蛋白酶原(PG)水平情况进行对比分析。结果经过12周治疗后,实验组临床疗效优于对照组,差异具有统计学意义(P<0.05);治疗后2组PGI、PGR水平均升高(P<0.05),与对照组相比,试验组PGI、PGR水平较高(P<0.05)。结论叶酸、腺苷钴胺联合胃复春治疗幽门螺杆菌阴性慢性萎缩性胃炎的临床疗效显著,有效提高患者血清胃蛋白酶原Ⅰ水平,值得在临床上进一步推广应用。Objective To investigate the clinical efficacy of folic acid, cobamamide combined with Weifunchun in the treatment of helicobacter pylorinegative chronic atrophic gastritis. Methods From May 2015 to August 2016, 74 helicobacter pylori-negative patients with chronic atrophic gastritis in our hospital were divided into two groups： control group and experiment group, with 37 cases in each group. The control group was treated with Weifunchun, the experiment group treated with folic acid, cobamamide and Weifunchun, the two groups of treatment efficiency and pepsinogen（PG） levels were analyzed. Results After treatment, the experiment group was better than the control group, the difference was statistically significant（P〈0.05）. Compared with before treatment, the PGI and PGR level of in each group were higher（P〈0.05）. And the PGI and PGR level of the experiment group were higher than the control group.（P〈0.05）. Conclusion Folic acid, cobamamide combined with Weifunchun in the treatment of helicobacter pylori-negative chronic atrophic gastritis of the clinical efficacy is significant, effectively improve the serum PGI level and safety, worthy of further clinical application.

关 键 词：幽门螺杆菌 叶酸 腺苷钴胺 胃复春 慢性萎缩性胃炎 

分 类 号：R573.32[医药卫生—消化系统]